Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-12-05FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Bausch & Lomb Incorporated)
FDA approved the original application for olopatadine hydrochloride ophthalmic solution from Bausch & Lomb. This antihistamine eye drop is i…
-
FDA approval · 2017-12-05FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Apotex Corp.)
FDA approved the original ANDA for olopatadine hydrochloride ophthalmic solution from Apotex Corp., a generic antihistamine for allergic con…
-
CLINICAL_TRIALS trial_result · 2017-11-09Clinical Trial Update: A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle [Phase 3]
Phase 3 study evaluating onset and duration of action of AC-170 0.24% versus vehicle in allergic conjunctivitis has completed with results p…
-
CLINICAL_TRIALS trial_result · 2017-10-10Clinical Trial Update: A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle [Phase 3]
A Phase 3 clinical trial evaluating the onset and duration of action of AC-170 0.24% versus vehicle for allergic conjunctivitis was complete…
-
CLINICAL_TRIALS trial_result · 2017-10-03Clinical Trial Update: A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) [Phase 3]
A Phase 3 multi-center trial evaluating onset and duration of action of AC-170 0.24% versus vehicle in the conjunctival allergen challenge h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-09-14Clinical Trial Update: Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model [Phase 2]
Phase 2 trial evaluating AC-150 for allergic conjunctivitis completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-08-30Clinical Trial Update: Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating AC-170 for allergic conjunctivitis using the conjunctival allergen challenge model has completed and res…
-
CLINICAL_TRIALS trial_result · 2017-08-18Clinical Trial Update: Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis [Phase 2]
This clinical trial update reports the termination of a Phase 2 study evaluating hydrocortisone ophthalmic ointment 0.5% for allergic conjun…
-
FDA approval · 2017-08-18FDA Approved: AZELASTINE — Original Application (Ascend Laboratories, LLC)
The FDA approved the original application for azelastine, a generic antihistamine, submitted by Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2017-08-14Clinical Trial Update: Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis [Phase 3]
Phase 3 clinical trial evaluating olopatadine 0.2% for allergic conjunctivitis has completed.
-
CLINICAL_TRIALS trial_result · 2017-07-26Clinical Trial Update: A Multi-Center Study Evaluating the Safety of AC-170 0.24% [Phase 3]
A Phase 3 trial evaluating the safety of AC-170 0.24% in atopic disease including allergic conjunctivitis has completed with results posted …
-
FDA approval · 2017-07-26FDA Approved: OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION — Original Application (Bausch & Lomb Incorporated)
FDA approved an original Abbreviated New Drug Application for olopatadine hydrochloride ophthalmic solution by Bausch & Lomb for relief of i…
-
CLINICAL_TRIALS research · 2017-07-26Clinical Trial Update: Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
An observational study evaluating Oralair grass pollen immunotherapy in children aged 5-9 with grass pollen–induced allergic rhinitis with o…
-
EMA approval · 2017-07-21New medicine for rare form of eye allergy in children and teenagers
EMA approves a new medicine for a rare form of eye allergy in children and teenagers, expanding treatment options for this condition.
-
CLINICAL_TRIALS trial_result · 2017-07-12Clinical Trial Update: Olopatadine Eye Drops and Allergy Skin Testing [NA]
This clinical trial update reports completion and posted results for a study of olopatadine eye drops and allergy skin testing in allergic r…
-
FDA approval · 2017-06-28FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (GLENMARK THERAPEUTICS INC., USA)
FDA approves Glenmark's generic olopatadine hydrochloride ophthalmic solution for allergic conjunctivitis in an Original Application.
-
FDA approval · 2017-05-30FDA Approved: ZERVIATE — Original Application (Harrow Eye, LLC)
FDA approved ZERVIATE (cetirizine ophthalmic solution) via its original application by Harrow Eye, LLC for the treatment of allergic conjunc…
-
FDA approval · 2017-05-04FDA Approved: PRED FORTE — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Pred Forte (prednisolone acetate ophthalmic suspension) from Allergan, updating/expanding its la…
-
CLINICAL_TRIALS trial_result · 2017-02-24Clinical Trial Update: Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis [Phase 2]
A Phase 2 efficacy study evaluating three concentrations of SAR 1118 in allergic conjunctivitis has completed with results posted.
-
FDA approval · 2017-01-31FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved OLOPATADINE HYDROCHLORIDE ophthalmic solution under an Original Application for allergic conjunctivitis. The applicant is Padag…
-
CLINICAL_TRIALS trial_result · 2017-01-24Clinical Trial Update: Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis [Phase 1]
A Phase 1 study evaluated the safety and tolerability of XmAb7195 in healthy adults and adults with allergic rhinitis, allergic conjunctivit…
-
FDA approval · 2017-01-06FDA Approved: VISINE ALLERGY EYE RELIEF MULTI-ACTION — Supplemental Application (Kenvue Brands LLC)
The FDA approved a supplemental application for Visine Allergy Eye Relief Multi-Action, a combination eye drop containing naphazoline hydroc…
-
FDA approval · 2016-12-22FDA Approved: AZELASTINE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for azelastine hydrochloride from Sun Pharmaceutical Industries, updating the approved generic p…
-
CLINICAL_TRIALS research · 2016-12-16Clinical Trial Update: Patient Perception Study for AL-4943A [Phase 4]
Alcon's Phase 4 patient-perception study of AL-4943A for allergic conjunctivitis has completed, per the trial registry update.
-
CLINICAL_TRIALS trial_result · 2016-11-22Clinical Trial Update: Mast-Cell Stabilizing Effects of Olopatadine [Phase 4]
Phase 4 clinical trial assessing whether olopatadine stabilizes mast cells in allergic conjunctivitis; the study status is completed.